Mechanism of Action: Somatostatin Receptor Agonists
✉ Email this page to a colleague
Drugs with Mechanism of Action: Somatostatin Receptor Agonists
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 215395-002 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 215395-003 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 217193-001 | May 21, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 217193-002 | May 21, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 217193-003 | May 21, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Invagen Pharms | LANREOTIDE ACETATE | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 215395-001 | Dec 17, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
